Skip to main content


An AI firm wants to predict costly pharma flops

By Bloomberg  
   April 12, 2019

Before Biogen Inc.’s experimental Alzheimer’s disease drug failed in a trial last month, analysts surveyed by Bloomberg estimated annual sales of about $3.7 billion by 2023. A German artificial-intelligence firm had come to a different conclusion.

Full story

Get the latest on healthcare leadership in your inbox.